Albumin variants
AssigneeAlbumedix Ltd
InventorsJason Cameron, Karen Ann Delahay, Jens Erik Nielsen, Andrew Plumridge, Jan Terje Andersen
Life of this patent
Estimating the term…
Abstract
The present invention relates to variants of a parent albumin, the variants having altered plasma half-life compared with the parent albumin. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
Claims25
A method of altering the binding activity of a polypeptide, which is a variant of albumin, a fragment thereof or a fusion polypeptide comprising said variant albumin or fragment thereof, to FcRn as compared with the FcRn binding activity of a parent albumin, reference albumin, fragment thereof or a fusion polypeptide comprising said parent albumin, reference albumin or fragment or fusion thereof, comprising contacting FcRn with said polypeptide, wherein said polypeptide further comprises a substitution to K, L, or M at a position corresponding to 550 in SEQ ID NO:
- 2, a substitution to P, Y, W, H, F, T, I, or V at a position corresponding to 573 in SEQ ID NO:
- 2, and a substitution to K or R at a position corresponding to 580 in SEQ ID NO:
- 2, wherein said polypeptide has a stronger binding affinity to FcRn or longer plasma half-life than a parent albumin, reference albumin, fragment thereof or fusion polypeptide comprising said parent albumin, reference albumin or fragment or fusion thereof.
A method for altering the circulating half-life of a molecule comprising providing a variant of albumin, a fragment thereof or a fusion polypeptide comprising said variant albumin or fragment thereof;
- and
- a) where the molecule is a polypeptide, fusing or conjugating the molecule to said variant of albumin, fragment thereof or fusion polypeptide comprising said variant albumin or fragment thereof;
- or
- b) where the molecule is not a polypeptide, conjugating the molecule to said variant of albumin, fragment thereof or fusion polypeptide comprising said variant albumin or fragment thereof;
- or
- c) contacting the molecule with said variant of albumin, fragment thereof or fusion polypeptide comprising said variant albumin or fragment thereof, wherein said contacting results in a noncovalent association between said molecule and variant of albumin, fragment thereof or fusion polypeptide comprising said variant albumin or fragment thereof;
- wherein said variant of albumin, fragment thereof or fusion polypeptide comprising said variant albumin or fragment thereof comprises a substitution to K, L, or M at a position corresponding to 550 in SEQ ID NO:
- 2, a substitution to P, Y, W, H, F, T, I, or V at a position corresponding to 573 in SEQ ID NO:
- 2, and a substitution to K or R at a position corresponding to 580 in SEQ ID NO:
- 2, wherein said polypeptide has a stronger binding affinity to FcRn or longer plasma half-life than a parent albumin, reference albumin, fragment thereof or fusion polypeptide comprising said parent albumin, reference albumin or fragment or fusion thereof.
Dependencies are inferred from the claim text.